Core Viewpoint - Hefei Qizhong Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 75 million to RMB 150 million, utilizing over-raised funds, self-owned funds, and a special loan from CITIC Bank [1][5][15] Summary by Sections Repurchase Plan - The repurchase amount is set between RMB 75 million and RMB 150 million [1][5] - The funding sources include over-raised funds, self-owned funds, and a special loan from CITIC Bank [1][5] - The maximum repurchase price is capped at RMB 16.61 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [4][8] - The repurchase will be conducted via centralized bidding on the Shanghai Stock Exchange [4][6] Implementation Procedures - The proposal was initiated by the general manager, Yang Zongming, and approved by the board with unanimous consent [2][3] - The repurchase period is set for 12 months from the board's approval date [4][5] - The repurchase is intended for employee stock ownership plans or equity incentive programs [4][5] Financial Impact - The repurchase is expected to involve approximately 451,540 to 903,070 shares, representing 0.38% to 0.76% of the total share capital [5][7] - The total amount of RMB 150 million represents 2.48% of the company's current liquid assets [9] Shareholder Considerations - Major shareholders, including Hefei Qizhong Holdings Co., Ltd. and others, have no plans to reduce their holdings in the next three to six months [4][10] - The board's decision does not require shareholder approval, as it meets the necessary quorum [3][15] Future Plans - The repurchased shares will be used for employee stock ownership plans or equity incentives, with a commitment to disclose any changes in plans or shareholding [12][14] - The company will ensure compliance with legal requirements regarding the repurchase and potential cancellation of untransferred shares [12][14]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688352 证券简称：颀中科技 公告编号：2025-031 合肥颀中科技股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 合肥颀中科技股份有限公司（以下简称"公司"）拟通过集中竞价交易方式回购 部分公司已发行的人民币普通股（A 股）股票，回购方案具体如下： ● 回购股份金额：不低于人民币 7,500 万元（含），不超过人民币 15,000 万元（含）； ● 回购股份资金来源：超募资金、自有资金及中信银行股份有限公司合肥分行（以 下简称"中信银行"）提供的股票回购专项贷款； ● 回购股份期限：自公司董事会审议通过本次回购方案之日起 12 个月内； ● 相关股东是否存在减持计划：截至本公告披露日，公司控股股东合肥颀中科技 控股有限公司，持股 5%以上的股东 Chipmore Holding Company Limited、合肥芯屏 产业投资基金（有限合伙）未来 3 个月、未来 6 个月内不存在减持公司股票计划； 公司回购提议人、董事、监事、 ...

Core Viewpoint - Company Qizhong Technology plans to raise up to 850 million yuan through convertible bonds to invest in two projects aimed at enhancing its advanced packaging and testing capabilities for integrated circuits [1][5]. Investment Projects - The total investment for the high-pin-count micro-sized bump packaging and testing project is approximately 41.95 million yuan, with the company planning to use 41.9 million yuan from the raised funds [3]. - The advanced power and flip-chip packaging technology renovation project at Qizhong Technology (Suzhou) has a total investment of about 43.17 million yuan, with 43.1 million yuan expected to be funded from the new issuance [3]. - The combined total investment for both projects is around 85.11 million yuan, with the company intending to utilize 85 million yuan from the fundraising [3]. Business Focus and Market Position - Over half of the raised funds will be allocated to enhance the packaging and testing capacity for non-display chips, which currently contribute less than 10% to the company's revenue in 2024 [5]. - Qizhong Technology is one of the few domestic firms capable of large-scale production of various bump manufacturing technologies and has maintained a leading position in advanced packaging technology [6]. - The company reported a projected revenue of nearly 2 billion yuan in 2024, with its display driver chip packaging business expected to sell 1.845 billion units, generating 1.758 billion yuan in revenue, ranking third globally in this sector [6]. Financial Performance and Stock Status - Since its IPO in April 2023, Qizhong Technology's stock has underperformed, trading below its initial offering price of 12.1 yuan per share, with a notable drop to around 8 yuan [9]. - The company has experienced a decline in net profit, reporting 313 million yuan in 2024, a decrease of 15.71% year-on-year, attributed to rising costs such as equipment depreciation and employee compensation [10]. - The company plans to repurchase shares at a price not exceeding 16.61 yuan per share, with a total repurchase amount between 75 million and 150 million yuan [9].

Core Viewpoint - Hefei Chipmore Technology Co., Ltd. is issuing convertible bonds to unspecified investors, with a focus on raising funds for technological advancements and business expansion in the semiconductor packaging industry. Group 1: Bond Issuance Details - The company is issuing convertible bonds with a redemption clause, including both maturity redemption and conditional redemption, with the redemption price to be determined based on market conditions at the time of issuance [3] - The company emphasizes that the convertible bonds are not guaranteed, which may pose repayment risks if adverse events impact the company's operations [4] Group 2: Credit Rating - The credit rating agency Dongfang Jincheng has rated the company's credit as "AA+" with a stable outlook for the convertible bonds [4] Group 3: Risks Associated with Technology and Market - The company faces risks related to technological upgrades and product iterations, particularly in the integrated circuit industry, where performance demands are increasing [4][5] - There is a risk of unfavorable market conditions affecting the development of non-display business segments, which are currently smaller in scale compared to competitors [6] - Increased competition in the semiconductor packaging industry may adversely affect the company's business development and operational performance [6] Group 4: Fund Utilization and Project Risks - The funds raised will be invested in projects such as advanced power and flip-chip packaging technology, which are crucial for enhancing the company's production capabilities [7][9] - There are risks associated with the timely availability of funds and potential delays in project implementation, which could impact the company's operational efficiency [8][9] Group 5: Measures to Mitigate Immediate Return Dilution - The company plans to implement various measures to protect investors' interests and mitigate the potential dilution of immediate returns from the bond issuance [10][12] - The company commits to strict governance and management practices to ensure effective use of the raised funds and to enhance its profitability and core competitiveness [10][11]

证券代码：688352 证券简称：颀中科技 合肥颀中科技股份有限公司 Hefei Chipmore Technology Co.,Ltd. （安徽省合肥市新站区综合保税区大禹路 2350 号） 向不特定对象发行可转换公司债券 募集说明书 （申报稿） 保荐机构（主承销商） （北京市朝阳区安立路 66 号 4 号楼） 二〇二五年六月 合肥颀中科技股份有限公司 募集说明书（申报稿） 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证 ...

关于向不特定对象发行可转换公司债券申请 获得上海证券交易所受理的公告 证券代码：688352 证券简称：颀中科技 公告编号：2025-030 合肥颀中科技股份有限公司 公司本次向不特定对象发行可转换公司债券事项尚需通过上交所审核，并获 得中国证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方 可实施。最终能否通过上交所审核，并获得中国证监会同意注册的决定及时间尚 存在不确定性。公司将根据该事项的进展情况，按照相关规定和要求及时履行信 息披露义务，敬请广大投资者注意投资风险。 特此公告。 合肥颀中科技股份有限公司董事会 2025 年 6 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 合肥颀中科技股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日收到上 海证券交易所（以下简称"上交所"）出具的《关于受理合肥颀中科技股份有限公 司科创板上市公司发行证券申请的通知》（上证科审（再融资）〔2025〕69 号）， 上交所对公司报送的科创板上市公司发行证券的募集说明书及相关申请文件进 行了 ...

中信建投证券股份有限公司 关于 合肥颀中科技股份有限公司 向不特定对象发行可转换公司债券 之 发行保荐书 保荐人 二〇二五年六月 保荐人出具的证券发行保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人吴建航、廖小龙根据《中华 人民共和国公司法》《中华人民共和国证券法》等有关法律、法规和中国证监会 的有关规定以及上海证券交易所的有关业务规则，诚实守信，勤勉尽责，严格按 照依法制订的业务规则、行业执业规范和道德准则出具本发行保荐书，并保证发 行保荐书的真实性、准确性和完整性。 3-1-1 | 释 | 义 3 | | --- | --- | | | 一、一般释义 3 | | | 二、专业术语释义 3 | | 第一节 | 本次证券发行基本情况 5 | | | 一、本次证券发行具体负责推荐的保荐代表人 5 | | | 二、本次证券发行项目协办人及项目组其他成员 5 | | | 三、发行人基本情况 6 | | | 四、保荐人与发行人关联关系的说明 10 | | | 五、保荐人内部审核程序和内核意见 11 | | | 六、保荐人对私募投资基金备案情况的核查 12 | | 第二节 | 保荐人承诺事项 ...

中信建投证券股份有限公司 关于 合肥颀中科技股份有限公司 向不特定对象发行可转换公司债券 之 上市保荐书 保荐人 二〇二五年六月 保荐人出具的上市保荐书 保荐人及保荐代表人声明 中信建投证券股份有限公司及本项目保荐代表人吴建航、廖小龙已根据《中 华人民共和国公司法》《中华人民共和国证券法》等法律法规和中国证监会及上 海证券交易所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则 和行业自律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 3-2-1 | 释 义 3 | | --- | | 一、发行人基本情况 6 | | 二、发行人本次发行情况 33 | | 三、本次证券发行上市保荐代表人、协办人及项目组其他成员情况、联系地址、 | | 电话和其他通讯方式 34 | | 四、关于保荐人是否存在可能影响公正履行保荐职责情形的说明 36 | | 五、保荐人按照有关规定应当承诺的事项 37 | | 六、保荐人关于发行人是否已就本次证券发行上市履行了《公司法》《证券法》 | | 和中国证监会及上海证券交易所规定的决策程序的说明 38 | | 七、保荐人关于发行人是否符合板块定位及国家产业政策所作出的专业判 ...

合 肥 颀 中 科 技 股 份 有 限 公 司 审 计 报 告 天 职 业 字 [2023]4837 号 目 录 审计报告 1 2 0 2 2 年 度 财 务 报 表 5 2 0 2 2 年 度 财务报表附注 1 7 6-1-1 审计报告 天职业字[2023]4837 号 合肥颀中科技股份有限公司全体股东： 一、审计意见 我们审计了合肥颀中科技股份有限公司（以下简称"贵公司"或"颀中科技"）财务报 表，包括 2022 年 12 月 31 日的合并及母公司资产负债表，2022 年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表，以及财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 贵公司 2022 年 12 月 31 日的合并及母公司财务状况以及 2022 年度的合并及母公司经营成果 和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计师对 财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照中国注册会计师职 业道德守则，我们独立于贵公司，并履行了职业道德方面的其他责任。 ...